Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) Sees Large Decline in Short Interest

Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 77,600 shares, a drop of 72.7% from the August 15th total of 284,000 shares. Based on an average daily trading volume, of 200 shares, the short-interest ratio is currently 388.0 days.

HKMPF remained flat at $$34.30 during midday trading on Wednesday. The firm has a market capitalization of $8.31 billion, a P/E ratio of 20.06 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.87 and a debt-to-equity ratio of 0.36. Hikma Pharmaceuticals has a 12-month low of $30.15 and a 12-month high of $37.70. The firm’s fifty day moving average is $35.24 and its two-hundred day moving average is $33.79.

The firm also recently declared a Semi-Annual dividend, which will be paid on Monday, September 20th. Shareholders of record on Friday, August 20th will be paid a dividend of $0.18 per share. The ex-dividend date of this dividend is Thursday, August 19th.

Several research firms recently weighed in on HKMPF. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals in a research note on Friday, August 20th. Morgan Stanley cut shares of Hikma Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a research note on Monday, August 9th. Zacks Investment Research cut shares of Hikma Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, September 9th. Citigroup reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Thursday, July 1st. Finally, restated a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Thursday, July 1st. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $38.00.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa.

Featured Story: What moving averages are used to define a golden cross?

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.